About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Atlanta | 9,468 Studies Near You | Clareo Health

Clinical Trials LocationsAtlanta

Clinical Trials in Atlanta

Discover 9,468 clinical trials near Atlanta, Georgia. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 3441-3460 of 9,468 trials

TERMINATEDPhase 1/2< 1 mile

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

NCT04990388

The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).

Glycogen Storage Disease Type III

Ultragenyx Pharmaceutical Inc9 participantsStarted Oct 2021

Orange, California, United States • Atlanta, Georgia, United States • Philadelphia, Pennsylvania, United States +3 more locations

COMPLETEDPhase 3< 1 mile

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

NCT04279314

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome

ACADIA Pharmaceuticals Inc.154 participantsStarted Jan 2020

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +18 more locations

Find Trials by Condition in Atlanta

Breast Cancerin Atlanta Lung Cancerin Atlanta Prostate Cancerin Atlanta Colorectal Cancerin Atlanta Melanomain Atlanta Leukemiain Atlanta Lymphomain Atlanta Pancreatic Cancerin Atlanta Ovarian Cancerin Atlanta Brain Cancerin Atlanta Diabetes

Data from ClinicalTrials.govTerms

TERMINATEDPhase 217 miles

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

NCT04171765

This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).

Non-alcoholic Steatohepatitis

Genentech, Inc.46 participantsStarted Sep 2020

Cullman, Alabama, United States • Chandler, Arizona, United States • Tucson, Arizona, United States +50 more locations

TERMINATEDPhase 227 miles

A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)

NCT03448692

The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.

Focal Segmental Glomerulosclerosis (FSGS)

Pfizer47 participantsStarted Oct 2018

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +107 more locations

COMPLETEDNA137 miles

Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer

NCT02054741

This cluster randomized clinical trial compares a geriatric assessment intervention with usual care for reducing cancer treatment toxicity in older patients with cancer that has spread to other places in the body. A geriatric assessment may identify risk factors for cancer treatment toxicity and may improve outcomes for older patients with advanced cancer.

Adult Solid NeoplasmToxicityLymphoma

Supriya Mohile733 participantsStarted Jul 2014

Duarte, California, United States • Newark, Delaware, United States • Honolulu, Hawaii, United States +20 more locations

COMPLETEDNA140 miles

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

NCT01564368

RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating how well patients with breast cancer respond to treatment. PURPOSE: This research trial studies DWI and DCE-MRI in assessing treatment response in patients with breast cancer undergoing neoadjuvant chemotherapy.

American College of Radiology Imaging Network406 participantsStarted Aug 2012

Birmingham, Alabama, United States • San Francisco, California, United States • Minneapolis, Minnesota, United States +4 more locations

Active Not RecruitingNA193 miles

Study Using Negative Pressure to Reduce Apnea

NCT04861038

The objective of this study is to determine the safety and effectiveness of the aerSleep® II device for treatment of moderate to severe Obstructive Sleep Apnea (OSA) over 24 weeks of home use in spontaneously breathing adult subjects who are intolerant of Continuous Positive Airway Pressure (CPAP) therapy.

Sleep Apnea, ObstructiveApnea, Sleep

Sommetrics, Inc.900 participantsStarted Nov 2021

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +12 more locations

COMPLETED204 miles

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

NCT02389855

The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. Since receiving FDA clearance in April 2013, the NBS has been used in nearly 300 procedures conducted at approximately 20 leading institutions across the United States. This post-market, multi-center retrospective study is designed to collect long-term follow-up data on patients who were treated previously with NBS.

Primary Brain Tumor

Monteris Medical144 participantsStarted Feb 2015

New Haven, Connecticut, United States • Kansas City, Kansas, United States • Kansas City, Missouri, United States +6 more locations

TERMINATED226 miles

Real-World Data Study to Understand Participant Treatment Outcomes for Dupuytren's Contracture

NCT05877066

This is an observational study, meaning participants will not receive any investigational treatment as part of this study. Researchers will collect real-world data (RWD), based on usual care, to gain a more in-depth knowledge of the natural history and the treatment outcomes of Dupuytren's Contracture (DC) to evaluate the management of DC.

Dupuytren's Contracture

Endo Pharmaceuticals130 participantsStarted Jun 2023

Phoenix, Arizona, United States • Greenwich, Connecticut, United States • Temple Terrace, Florida, United States +4 more locations

TERMINATEDPhase 1285 miles

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

NCT02880410

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation therapy and temozolomide for the treatment of newly diagnosed glioblastomas (GBM).

Monteris Medical3 participantsStarted Aug 2017

St Louis, Missouri, United States • Winston-Salem, North Carolina, United States • Cleveland, Ohio, United States +1 more locations

Active Not RecruitingNA316 miles

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

BPH (Benign Prostatic Hyperplasia)Lower Urinary Tract Symptoms (LUTS)

Zenflow, Inc.279 participantsStarted Sep 2021

Los Angeles, California, United States • Glenview, Illinois, United States • Las Vegas, Nevada, United States +4 more locations

COMPLETEDPhase 1371 miles

Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age

NCT05489328

The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.

Pneumococcal Disease

Pfizer394 participantsStarted Aug 2022

Tustin, California, United States • Walnut Creek, California, United States • Milford, Connecticut, United States +15 more locations

COMPLETEDPhase 1481 miles

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

NCT05001516

A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors

Advanced Solid Tumor

Turning Point Therapeutics, Inc.17 participantsStarted Dec 2021

Duarte, California, United States • Fullerton, California, United States • Lafayette, Indiana, United States +4 more locations

COMPLETEDPhase 1522 miles

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

NCT04536792

The purpose of the study is to assess the safety and tolerability of AG-946 in healthy volunteers after oral administration of single ascending doses (SAD) and multiple ascending doses (MAD) of AG-946 over 14 or up to 28 days of dosing, and to identify a range of doses that are safe and pharmacologically active in participants with sickle cell disease. The SAD and MAD parts of the study will be randomized and double-blinded, and will assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of AG-946 as well as the effect of food (SAD only) on the pharmacokinetics (PK) of AG-946. The sickle cell disease (SCD) part of the study will be non-randomized and open-label, and is designed to identify 1 or more safe and tolerable dose(s) of AG-946 with potential activity in the treatment of participants with sickle cell disease (SCD).

Healthy VolunteersAnemia, Sickle Cell

Agios Pharmaceuticals, Inc.122 participantsStarted Jul 2020

La Jolla, California, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States +7 more locations

RECRUITINGPhase 1/2528 miles

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

NCT05519293

This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).

Non-small Cell Lung Cancer

RedCloud Bio76 participantsStarted Dec 2022

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +1 more locations

COMPLETEDPhase 1606 miles

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

NCT04593121

The primary objective is to determine the safety and tolerability of single and multiple ascending subcutaneous (SC) doses and a single intravenous (IV) dose of BIIB107 in healthy adult participants. The secondary objectives are to characterize the single-dose pharmacokinetic (PK) of SC and IV BIIB107 in healthy adult participants and to characterize the multiple-dose PK of SC BIIB107 in healthy adult participants.

Healthy Volunteers

Biogen84 participantsStarted Oct 2020

Anaheim, California, United States • Miami, Florida, United States • Overland Park, Kansas, United States

RECRUITINGPhase 1669 miles

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

NCT06361485

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

R3 Stem Cell100 participantsStarted Mar 2024

Scottsdale, Arizona, United States • Beverly Hills, California, United States • New York, New York, United States +1 more locations

COMPLETED746 miles

Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

NCT03761615

The overall goal of this study is to enroll pregnant women with type 1 diabetes and follow their glycemic outcomes prospectively throughout pregnancy and into the post-partum period. The investigators anticipate that when compared to subjects using an Artificial pancreas system (AP) as part of a future protocol, this comparator group of subjects undergoing usual care will exhibit less time in target continuous glucose monitoring (CGM) glucose range defined as 63-140 mg/dL and an increased duration of hypoglycemia with CGM glucose \<63 mg/dL.

Type 1 Diabetes MellitusPregnancy in Diabetics

Sansum Diabetes Research Institute25 participantsStarted Nov 2018

Santa Barbara, California, United States • Rochester, Minnesota, United States • New York, New York, United States

TERMINATEDPhase 1746 miles

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 \[PD-1\] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them. The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

Renal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more

Pfizer13 participantsStarted Oct 2021

Duarte, California, United States • New York, New York, United States • New York, New York, United States

Active Not RecruitingNA1933 miles

Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies

NCT03682029

The primary purpose of this multi-centre, randomized, placebo-controlled, double-blind phase II study is to investigate if oral vitamin C may change the biology of low-risk myeloid malignancies; i.e., clonal cytopenia of undetermined significance (CCUS), low-risk myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)-0/1 by reversing the epigenetic changes characteristic of these disease entities. The epigenetic regulator TET2 is the gene most often affected in CCUS. Preclinical studies have shown that active demethylation by the TET enzymes is dependent on vitamin C, and the investigators and collaborators have shown that plasma vitamin C levels are exceedingly low in hematological cancer patients but are easily corrected by oral vitamin C. This study is part of an array of EVITA studies aimed at clarifying whether the standard of care of patients with myeloid malignancies should be changed and oral vitamin C supplement added to the treatment recommendations.

Myelodysplastic SyndromesChronic Myelomonocytic Leukemia-1Cytopenia

Rigshospitalet, Denmark109 participantsStarted Nov 2017

Los Angeles, California, United States • Copenhagen, N/A = Not Applicable, Denmark • Aalborg, Denmark +2 more locations

PreviousPage 173 of 474Next

in Atlanta

Heart Diseasein Atlanta